|
Volumn 120, Issue 4, 2002, Pages 99-
|
Should we spend less or control a greater percentage of hypertensive patients?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIHYPERTENSIVE AGENT;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CALCIUM CHANNEL BLOCKING AGENT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIURETIC AGENT;
BLOOD PRESSURE MEASUREMENT;
COST EFFECTIVENESS ANALYSIS;
DRUG EFFICACY;
EDITORIAL;
HEALTH CARE COST;
HEALTH SURVEY;
HUMAN;
HYPERTENSION;
INCIDENCE;
PATIENT COMPLIANCE;
POPULATION BASED CASE CONTROL STUDY;
QUALITY OF LIFE;
BRAZIL;
COST BENEFIT ANALYSIS;
DRUG COST;
ECONOMICS;
NOTE;
TREATMENT REFUSAL;
ANTIHYPERTENSIVE AGENTS;
BRAZIL;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
HUMANS;
HYPERTENSION;
TREATMENT REFUSAL;
|
EID: 0037019428
PISSN: 15163180
EISSN: 15163180
Source Type: Journal
DOI: 10.1590/s1516-31802002000400001 Document Type: Editorial |
Times cited : (2)
|
References (6)
|